Don't pay just to have an ISA. Find out more
(CBF.L) Cobra Bio-Manufacturing PLC Buy/Sell
Add to portfolio Set Alert Level 2 Desktop Trader
Summary
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
| Date/Time | Headline | Source |
|---|---|---|
| 05-03-10 | RNS |
|
|
RNS Number : 1131I AIM 05 March 2010
NOTICE (115) 05/03/2010 7:00am
CANCELLATION OF ADMISSION OF SECURITIES TO TRADING ON AIM
COBRA BIO-MANUFACTURING PLC At the request of the company, trading on AIM for the under-mentioned securities has been cancelled from 05/03/2010 7:00am.
Ordinary Shares of 1p each (3-170-483)(GB0031704835)
If you have any queries relating to the above, please contact the company's nominated adviser on 020 7107 8000.
AIM REGULATION
This information is provided by RNS The company news service from the London Stock Exchange END
AMOEZLFBBXFEBBB More |
||
| 04-03-10 | RNS |
|
|
RNS Number : 1054I Recipharm AB 04 March 2010 4 March 2010 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
FOR IMMEDIATE RELEASE
RECOMMENDED MANDATORY CASH OFFER UNDER RULE 9 OF THE CITY CODE TO ACQUIRE ORDINARY SHARES IN COBRA BIO-MANUFACTURING PLC MADE BY ACORN CORPORATE FINANCE LIMITED ON BEHALF OF RECIPHARM AB
OFFER UPDATE - OFFER EXTENDED INDEFINITELY AND LEVEL OF ACCEPTANCES Further to the announcement made by Recipharm AB ("Recipharm") on 17 February 2010 that its recommended mandatory cash offer for the entire issued and to be issued share capital of Cobra Bio-manufacturing Plc ("Cobra") had been declared wholly unconditional on 3 February 2010 and that the Offer had been extended to 1.00 p.m. (London Time) on 5 March 2010; Recipharm today announces that the Offer has been extended indefinitely. At least 14 days notice will be given in writing, to those Cobra Shareholders who have not then accepted, before the Offer is closed. Cobra Shareholders should note that an application has been made by Cobra to the London Stock Exchange for the cancellation of admission to trading on AIM of Cobra Shares. This cancellation will take effect from 7.00am on 5 March 2010. Accordingly today is the last day of dealings in Cobra Shares. The cancellation of the admission to trading of Cobra Shares on AIM will significantly reduce the liquidity and marketability of any Cobra Shares held by persons who have not accepted the Offer at that time and Cobra Shareholders should be aware that there will be no future market for a Cobra Shareholder to realise their investment in Cobra which is now under the control of Recipharm. Following the delisting and the cancellation of admission to trading of Cobra Shares on AIM, Cobra will be re-registered as a private limited company under the provisions of sections 97 to 101 of the Companies Act 2006. Since Recipharm now holds some 92.66 per cent of the issued share capital of Cobra, which is shortly to have its AIM trading facility cancelled and is in due course to be re-registered as a private limited company, Recipharm encourages Cobra Shareholders who have not already done so, to follow the recommendation of the Cobra Directors in accepting the Offer. The Offer Document in relation to the recommended mandatory cash offer made by Acorn Corporate Finance on behalf Recipharm for Cobra was posted to Cobra Shareholders on 13 January 2010. Level of acceptances and ownership At the time the Offer Document was posted, Recipharm held 19,450,000 Cobra Shares representing approximately 43.87 per cent of the issued share capital of Cobra. In addition, it had obtained irrevocable undertakings to accept, or to procure the acceptance of, the Offer from certain Cobra Directors in respect of 969,000 Cobra Shares being approximately 2.19 per cent. of Cobra's issued share capital ("Committed Shares"). In respect of the Committed Shares, as at 1.00 p.m. (London time) on 4 March 2010, valid acceptances had been received in respect of 969,000 Cobra Shares for the Offer being approximately 2.19 per cent. of the issued share capital of Cobra . In total, as at 1:00 p.m. (London time) on 4 March 2010, valid acceptances of the Offer had been received in respect of 21,638,719 Cobra Shares, representing approximately 48.80 per cent. of the issued share capital of Cobra. Therefore, taking into account the 19,450,000 Cobra Shares acquired by Recipharm on 16 December 2009, as at 1:00 pm (London time) on 4 March 2010, Recipharm either owned or had received valid acceptances in respect of 41,088,719 Cobra Shares, representing approximately 92.66 per cent. of the entire issued share capital of Cobra. Save as disclosed in this announcement neither Recipharm nor, so far as Recipharm is aware, any person acting or deemed to be acting in concert with Recipharm has any interest in any Cobra Shares (to which the Offer relates) or in any securities convertible into or exchangeable into Cobra Shares or has any rights to subscribe for Cobra Shares or holds any short position in relation to Cobra Shares (whether conditional or absolute and whether in the money or otherwise) including any short position under a derivative, any agreement to sell or any delivery obligation or right to require another person to purchase or take delivery, or has borrowed or on lent any Cobra Shares. The total number of Cobra Shares to which the Offer relates (and may therefore be counted by Recipharm towards the satisfaction of its acceptance condition) is 24,889,170 Recipharm also holds £180,000 of Convertible Loan Notes, which carry the right, in aggregate, to covert into 18,000,000 Ordinary Shares. Therefore, if Recipharm were to convert these Convertible Loan Notes, its holding, including those Cobra Shares already held and those Cobra Shares for which valid acceptances have been received, would be 59,088,719 Cobra Shares representing some 94.79 per cent. of the then issued share capital of Cobra. Procedure for acceptance To accept the Offer in respect of Cobra Shares held in certificated form, Cobra Shareholders should complete, sign and return the Form of Acceptance, which accompanied the Offer Document together with their share certificate(s), in accordance with the instructions contained therein and set out in the Offer Document, as soon as possible. To accept the Offer for Cobra Shares held in CREST, Cobra Shareholders should follow the procedure for electronic acceptance through CREST in accordance with the instructions set out in the Offer Document so that the TTE Instruction settles as soon as possible. Copies of the Offer Document, the Form of Acceptance and any information incorporated into it by reference to another source, are available by writing to Capita Registrars, Corporate Actions, The Registry, 34 Beckenham Road, Beckenham, Kent, BR3 4TU or calling on 0871 664 0321 or if calling from outside the UK, on +44 20 8639 3399 between 9.00am and 5.00pm (London time) Monday to Friday (except UK public holidays). while the Offer remains open for acceptance. Calls to the 0871 664 0321 number are charged at 10 pence per minute (including VAT) plus any of your service providers network extra charges. Capita Registrars cannot provide advice on the merits of the Offer nor give any financial, legal or tax advice. Settlement of consideration Settlement of consideration due under the Offer in respect of acceptances which have been received and are valid and complete in all respects will, in the case of certificated holders be dispatched by first class post (or by such other method as approved by the Panel) and in the case of uncertificated holders by crediting their CREST accounts, will be made within 14 days of the receipt of such acceptances. Compulsory acquisition As described in the Offer Document, once Recipharm receives valid acceptances under the Offer in respect of, or otherwise acquires, 90 per cent. or more of Cobra Shares to which the Offer relates, and 90 per cent. or more of the voting rights attaching to Cobra's issued share capital, Recipharm intends to exercise its rights pursuant to Sections 974 to 991(inclusive) of the Companies Act 2006, to acquire compulsorily the remaining Cobra Shares for which it has not received valid acceptances of the Offer or otherwise acquired. Terms defined in the Offer Document have the same meaning in this announcement. Acorn Corporate Finance Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for Recipharm and no-one else in connection with the Offer and will not be responsible to anyone other than Recipharm for providing the protections afforded to clients of Acorn Corporate Finance Limited nor for providing advice in relation to the Offer, the content of this announcement, or any transaction, arrangement or matter referenced herein. Seymour Pierce Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for Cobra and no-one else in connection with the Offer and will not be responsible to anyone other than Cobra for providing the protections afforded to clients of Seymour Pierce Limited nor for providing advice in relation to the Offer, the content of this announcement, or any transaction, arrangement or matter referenced herein. Copies of the Offer Document, the Form of Acceptance and other documents on display for the purposes of the Offer are available for inspection during normal business hours on any business day at the offices of Cobbetts LLP, 70 Grays Inn Road, London, WC1X 8BT, throughout the period during which the Offer remains open for acceptance. This announcement is not intended to and does not constitute, or form any part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor shall there be any sale, issue or transfer of the securities referred to in this announcement in any jurisdiction in contravention of any applicable law. The Offer is made solely by means of the Offer Document and, in the case of certificated Cobra Shares, the Form of Acceptance accompanying the Offer Document. The Offer will not be made directly or indirectly in or into the United States, Canada, Australia, the Republic of South Africa or Japan. Accordingly, copies of this announcement are not being, and must not be, mailed or otherwise distributed or sent in or into or from the United States, Canada, Australia, the Republic of South Africa or Japan. The availability of the Offer to persons outside the United Kingdom may be affected by the laws of other jurisdictions. Such persons should inform themselves about and observe any applicable requirements of those jurisdictions. The Offer Document is available on Recipharm's website www.recipharm.com and on Cobra's website at www.cobrabio.com. and will continue to be made available on these websites free of charge whilst the Offer remains open for acceptance. Dealing Disclosure Requirements Under the provisions of Rule 8.3 of the City Code, if any person is, or becomes, "interested" (directly or indirectly) in 1 per cent. or more of any class of "relevant securities" of Cobra, all " dealings" in any "relevant securities" of Cobra (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3.30 pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the Offer becomes unconditional as to acceptances, lapses or is otherwise withdrawn or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of Cobra, they will be deemed to be a single person for the purpose of Rule 8.3. Under the provisions of Rule 8.1 of the City Code, all "dealings" in "relevant securities" of Cobra by Recipharm, must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction. A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed, and the number of such securities in issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk. "Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities. Terms in quotation marks are defined in the City Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a "dealing' under Rule 8, you should consult the Panel. Enquiries:
Danny Chapchal, Chairman Simon Saxby, Chief Executive Peter Coleman, CFO and Company Secretary
Carl-Johan Spak, Vice President
(Financial Adviser, Nominated Adviser and
Broker to Cobra)
Chris Howard
Christopher Wren
(Financial Adviser to Recipharm)
Harry Dutson
Tim Anderson The Directors of Cobra accept responsibility for the information contained in this announcement relating to Cobra, the Cobra Directors and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the Directors of Cobra (who have taken all reasonable care to ensure that such is the case) the information contained in this announcement for which they are responsible is in accordance with the facts and does not omit anything likely to impact the import of this announcement. The Directors of Recipharm accept responsibility for the information contained in this announcement other than relating to Cobra, the Cobra Directors and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the Directors of Recipharm (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement for which they are responsible is in accordance with the facts and does not omit anything likely to affect the import of such information. This information is provided by RNS The company news service from the London Stock Exchange END
OUPUGUBCWUPUGCC More |
||
| 17-02-10 | RNS |
|
|
RNS Number : 3034H Recipharm AB 17 February 2010 17 February 2010 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
FOR IMMEDIATE RELEASE Correction to announcement made at 15 :17 on 17 February 2010 Only change is to the number of shares to which Offer applies
RECOMMENDED MANDATORY CASH OFFER UNDER RULE 9 OF THE CITY CODE TO ACQUIRE ORDINARY SHARES IN COBRA BIO-MANUFACTURING PLC MADE BY ACORN CORPORATE FINANCE LIMITED ON BEHALF OF RECIPHARM AB
OFFER UPDATE - OFFER EXTENDED AND LEVEL OF ACCEPTANCES Further to the announcement made by Recipharm AB ("Recipharm") on 3 February 2010 that its recommended mandatory cash offer for the entire issued and to be issued share capital of Cobra Bio-manufacturing Plc ("Cobra") had been declared wholly unconditional and had been extended to 1.00 p.m. (London Time) on 17 February 2010; in order to give remaining Cobra Shareholders a further opportunity to accept the Offer, Recipharm today announces that the offer has been extended until 1.00 p.m. (London Time) on 5 March 2010. Cobra Shareholders should note that an application has been made by Cobra to the London Stock Exchange for the cancellation of admission to trading on AIM of Cobra Shares. This cancellation will take effect from 7.00am on 5 March 2010. Accordingly the last day of dealings in Cobra Shares will be 4 March 2010. The cancellation of the admission to trading of Cobra Shares on AIM will significantly reduce the liquidity and marketability of any Cobra Shares held by persons who have not accepted the Offer at that time and Cobra Shareholders should be aware that there will be no future market for a Cobra Shareholder to realise their investment in Cobra which is now under the control of Recipharm. Accordingly, in order that Cobra Shareholders are not left holding unquoted Cobra Shares, Recipharm has extended the Offer until 1.00 p.m. (London Time) on 5 March 2010 and encourages all Cobra Shareholders, who have not already done so, to follow the recommendation of the Cobra Directors in accepting the offer. Following the delisting and the cancellation of admission to trading of Cobra Shares on AIM, Cobra will be re-registered as a private limited company under the provisions of sections 97 to 101 of the Companies Act 2006. The Offer Document in relation to the recommended mandatory cash offer made by Acorn Corporate Finance on behalf Recipharm for Cobra was posted to Cobra Shareholders on 13 January 2010. Level of acceptances and ownership At the time the Offer Document was posted, Recipharm held 19,450,000 Cobra Shares representing approximately 43.87 per cent of the issued share capital of Cobra. In addition, it had obtained irrevocable undertakings to accept, or to procure the acceptance of, the Offer from certain Cobra Directors in respect of 969,000 Cobra Shares being approximately 2.19 per cent. of Cobra's issued share capital ("Committed Shares"). In respect of the Committed Shares, as at 1.00 p.m. (London time) on 17 February 2010, valid acceptances had been received in respect of 969,000 Cobra Shares for the Offer being approximately 2.19 per cent. of the issued share capital of Cobra . In total, as at 1:00 p.m. (London time) on 17 February 2010, valid acceptances of the Offer had been received in respect of 20,847,275 Cobra Shares, representing approximately 47.01 per cent. of the issued share capital of Cobra. Therefore, taking into account the 19,450,000 Cobra Shares acquired by Recipharm on 16 December 2009, as at 1:00 pm (London time) on 17 February 2010, Recipharm either owned or had received valid acceptances in respect of 40,297,275 Cobra Shares, representing approximately 90.88 per cent. of the entire issued share capital of Cobra. Save as disclosed in this announcement neither Recipharm nor, so far as Recipharm is aware, any person acting or deemed to be acting in concert with Recipharm has any interest in any Cobra Shares (to which the Offer relates) or in any securities convertible into or exchangeable into Cobra Shares or has any rights to subscribe for Cobra Shares or holds any short position in relation to Cobra Shares (whether conditional or absolute and whether in the money or otherwise) including any short position under a derivative, any agreement to sell or any delivery obligation or right to require another person to purchase or take delivery, or has borrowed or on lent any Cobra Shares. The total number of Cobra Shares to which the Offer relates (and may therefore be counted by Recipharm towards the satisfaction of its acceptance condition) is 24,889,170 Recipharm also holds £180,000 of Convertible Loan Notes, which carry the right, in aggregate, to covert into 18,000,000 Ordinary Shares. Therefore, if Recipharm were to convert these Convertible Loan Notes, its holding, including those Cobra Shares already held and those Cobra Shares for which valid acceptances have been received, would be 58,297,275 Cobra Shares representing some 93.52 per cent. of the then issued share capital of Cobra. Procedure for acceptance To accept the Offer in respect of Cobra Shares held in certificated form, Cobra Shareholders should complete, sign and return the Form of Acceptance, which accompanied the Offer Document together with their share certificate(s), in accordance with the instructions contained therein and set out in the Offer Document, as soon as possible and, in any event, so as to be received by Capita Registrars by no later than 1.00pm (London time) on 5 March 2010. To accept the Offer for Cobra Shares held in CREST, Cobra Shareholders should follow the procedure for electronic acceptance through CREST in accordance with the instructions set out in the Offer Document so that the TTE Instruction settles as soon as possible and, in any event, by no later than 1.00pm (London time) on 5 March 2010. Copies of the Offer Document, the Form of Acceptance and any information incorporated into it by reference to another source, are available by writing to Capita Registrars, Corporate Actions, The Registry, 34 Beckenham Road, Beckenham, Kent, BR3 4TU or calling on 0871 664 0321 or if calling from outside the UK, on +44 20 8639 3399 between 9.00am and 5.00pm (London time) Monday to Friday (except UK public holidays). while the Offer remains open for acceptance. Calls to the 0871 664 0321 number are charged at 10 pence per minute (including VAT) plus any of your service providers network extra charges. Capita Registrars cannot provide advice on the merits of the Offer nor give any financial, legal or tax advice. Settlement of consideration Settlement of consideration due under the Offer in respect of acceptances which have been received and are valid and complete in all respects will, in the case of certificated holders be dispatched by first class post (or by such other method as approved by the Panel) and in the case of uncertificated holders by crediting their CREST accounts, will be made within 14 days of the receipt of such acceptances. Compulsory acquisition As described in the Offer Document, once Recipharm receives valid acceptances under the Offer in respect of, or otherwise acquires, 90 per cent. or more of Cobra Shares to which the Offer relates, and 90 per cent. or more of the voting rights attaching to Cobra's issued share capital, Recipharm intends to exercise its rights pursuant to Sections 974 to 991(inclusive) of the Companies Act 2006, to acquire compulsorily the remaining Cobra Shares for which it has not received valid acceptances of the Offer or otherwise acquired. Terms defined in the Offer Document have the same meaning in this announcement. Acorn Corporate Finance Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for Recipharm and no-one else in connection with the Offer and will not be responsible to anyone other than Recipharm for providing the protections afforded to clients of Acorn Corporate Finance Limited nor for providing advice in relation to the Offer, the content of this announcement, or any transaction, arrangement or matter referenced herein. Seymour Pierce Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for Cobra and no-one else in connection with the Offer and will not be responsible to anyone other than Cobra for providing the protections afforded to clients of Seymour Pierce Limited nor for providing advice in relation to the Offer, the content of this announcement, or any transaction, arrangement or matter referenced herein. Copies of the Offer Document, the Form of Acceptance and other documents on display for the purposes of the Offer are available for inspection during normal business hours on any business day at the offices of Cobbetts LLP, 70 Grays Inn Road, London, WC1X 8BT, throughout the period during which the Offer remains open for acceptance. This announcement is not intended to and does not constitute, or form any part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor shall there be any sale, issue or transfer of the securities referred to in this announcement in any jurisdiction in contravention of any applicable law. The Offer is made solely by means of the Offer Document and, in the case of certificated Cobra Shares, the Form of Acceptance accompanying the Offer Document. The Offer will not be made directly or indirectly in or into the United States, Canada, Australia, the Republic of South Africa or Japan. Accordingly, copies of this announcement are not being, and must not be, mailed or otherwise distributed or sent in or into or from the United States, Canada, Australia, the Republic of South Africa or Japan. The availability of the Offer to persons outside the United Kingdom may be affected by the laws of other jurisdictions. Such persons should inform themselves about and observe any applicable requirements of those jurisdictions. The Offer Document is available on Recipharm's website www.recipharm.com and on Cobra's website at www.cobrabio.com. and will continue to be made available on these websites free of charge whilst the Offer remains open for acceptance. Dealing Disclosure Requirements Under the provisions of Rule 8.3 of the City Code, if any person is, or becomes, "interested" (directly or indirectly) in 1 per cent. or more of any class of "relevant securities" of Cobra, all " dealings" in any "relevant securities" of Cobra (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3.30 pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the Offer becomes unconditional as to acceptances, lapses or is otherwise withdrawn or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of Cobra, they will be deemed to be a single person for the purpose of Rule 8.3. Under the provisions of Rule 8.1 of the City Code, all "dealings" in "relevant securities" of Cobra by Recipharm, must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction. A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed, and the number of such securities in issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk. "Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities. Terms in quotation marks are defined in the City Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a "dealing' under Rule 8, you should consult the Panel. Enquiries:
Danny Chapchal, Chairman Simon Saxby, Chief Executive Peter Coleman, CFO and Company Secretary
Carl-Johan Spak, Vice President
(Financial Adviser, Nominated Adviser and
Broker to Cobra)
Chris Howard
Christopher Wren
(Financial Adviser to Recipharm)
Harry Dutson
Tim Anderson The Directors of Cobra accept responsibility for the information contained in this announcement relating to Cobra, the Cobra Directors and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the Directors of Cobra (who have taken all reasonable care to ensure that such is the case) the information contained in this announcement for which they are responsible is in accordance with the facts and does not omit anything likely to impact the import of this announcement. The Directors of Recipharm accept responsibility for the information contained in this announcement other than relating to Cobra, the Cobra Directors and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the Directors of Recipharm (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement for which they are responsible is in accordance with the facts and does not omit anything likely to affect the import of such information. This information is provided by RNS The company news service from the London Stock Exchange END
OUPEDLFFBLFZBBK More |
||
| 17-02-10 | RNS |
|
|
RNS Number : 3002H Recipharm AB 17 February 2010 17 February 2010 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
FOR IMMEDIATE RELEASE
RECOMMENDED MANDATORY CASH OFFER UNDER RULE 9 OF THE CITY CODE TO ACQUIRE ORDINARY SHARES IN COBRA BIO-MANUFACTURING PLC MADE BY ACORN CORPORATE FINANCE LIMITED ON BEHALF OF RECIPHARM AB
OFFER UPDATE - OFFER EXTENDED AND LEVEL OF ACCEPTANCES Further to the announcement made by Recipharm AB ("Recipharm") on 3 February 2010 that its recommended mandatory cash offer for the entire issued and to be issued share capital of Cobra Bio-manufacturing Plc ("Cobra") had been declared wholly unconditional and had been extended to 1.00 p.m. (London Time) on 17 February 2010; in order to give remaining Cobra Shareholders a further opportunity to accept the Offer, Recipharm today announces that the offer has been extended until 1.00 p.m. (London Time) on 5 March 2010. Cobra Shareholders should note that an application has been made by Cobra to the London Stock Exchange for the cancellation of admission to trading on AIM of Cobra Shares. This cancellation will take effect from 7.00am on 5 March 2010. Accordingly the last day of dealings in Cobra Shares will be 4 March 2010. The cancellation of the admission to trading of Cobra Shares on AIM will significantly reduce the liquidity and marketability of any Cobra Shares held by persons who have not accepted the Offer at that time and Cobra Shareholders should be aware that there will be no future market for a Cobra Shareholder to realise their investment in Cobra which is now under the control of Recipharm. Accordingly, in order that Cobra Shareholders are not left holding unquoted Cobra Shares, Recipharm has extended the Offer until 1.00 p.m. (London Time) on 5 March 2010 and encourages all Cobra Shareholders, who have not already done so, to follow the recommendation of the Cobra Directors in accepting the offer. Following the delisting and the cancellation of admission to trading of Cobra Shares on AIM, Cobra will be re-registered as a private limited company under the provisions of sections 97 to 101 of the Companies Act 2006. The Offer Document in relation to the recommended mandatory cash offer made by Acorn Corporate Finance on behalf Recipharm for Cobra was posted to Cobra Shareholders on 13 January 2010. Level of acceptances and ownership At the time the Offer Document was posted, Recipharm held 19,450,000 Cobra Shares representing approximately 43.87 per cent of the issued share capital of Cobra. In addition, it had obtained irrevocable undertakings to accept, or to procure the acceptance of, the Offer from certain Cobra Directors in respect of 969,000 Cobra Shares being approximately 2.19 per cent. of Cobra's issued share capital ("Committed Shares"). In respect of the Committed Shares, as at 1.00 p.m. (London time) on 17 February 2010, valid acceptances had been received in respect of 969,000 Cobra Shares for the Offer being approximately 2.19 per cent. of the issued share capital of Cobra . In total, as at 1:00 p.m. (London time) on 17 February 2010, valid acceptances of the Offer had been received in respect of 20,847,275 Cobra Shares, representing approximately 47.01 per cent. of the issued share capital of Cobra. Therefore, taking into account the 19,450,000 Cobra Shares acquired by Recipharm on 16 December 2009, as at 1:00 pm (London time) on 17 February 2010, Recipharm either owned or had received valid acceptances in respect of 40,297,275 Cobra Shares, representing approximately 90.88 per cent. of the entire issued share capital of Cobra. Save as disclosed in this announcement neither Recipharm nor, so far as Recipharm is aware, any person acting or deemed to be acting in concert with Recipharm has any interest in any Cobra Shares (to which the Offer relates) or in any securities convertible into or exchangeable into Cobra Shares or has any rights to subscribe for Cobra Shares or holds any short position in relation to Cobra Shares (whether conditional or absolute and whether in the money or otherwise) including any short position under a derivative, any agreement to sell or any delivery obligation or right to require another person to purchase or take delivery, or has borrowed or on lent any Cobra Shares. The total number of Cobra Shares to which the Offer relates (and may therefore be counted by Recipharm towards the satisfaction of its acceptance condition) is 20,847,275. Recipharm also holds £180,000 of Convertible Loan Notes, which carry the right, in aggregate, to covert into 18,000,000 Ordinary Shares. Therefore, if Recipharm were to convert these Convertible Loan Notes, its holding, including those Cobra Shares already held and those Cobra Shares for which valid acceptances have been received, would be 58,297,275 Cobra Shares representing some 93.52 per cent. of the then issued share capital of Cobra. Procedure for acceptance To accept the Offer in respect of Cobra Shares held in certificated form, Cobra Shareholders should complete, sign and return the Form of Acceptance, which accompanied the Offer Document together with their share certificate(s), in accordance with the instructions contained therein and set out in the Offer Document, as soon as possible and, in any event, so as to be received by Capita Registrars by no later than 1.00pm (London time) on 5 March 2010. To accept the Offer for Cobra Shares held in CREST, Cobra Shareholders should follow the procedure for electronic acceptance through CREST in accordance with the instructions set out in the Offer Document so that the TTE Instruction settles as soon as possible and, in any event, by no later than 1.00pm (London time) on 5 March 2010. Copies of the Offer Document, the Form of Acceptance and any information incorporated into it by reference to another source, are available by writing to Capita Registrars, Corporate Actions, The Registry, 34 Beckenham Road, Beckenham, Kent, BR3 4TU or calling on 0871 664 0321 or if calling from outside the UK, on +44 20 8639 3399 between 9.00am and 5.00pm (London time) Monday to Friday (except UK public holidays). while the Offer remains open for acceptance. Calls to the 0871 664 0321 number are charged at 10 pence per minute (including VAT) plus any of your service providers network extra charges. Capita Registrars cannot provide advice on the merits of the Offer nor give any financial, legal or tax advice. Settlement of consideration Settlement of consideration due under the Offer in respect of acceptances which have been received and are valid and complete in all respects will, in the case of certificated holders be dispatched by first class post (or by such other method as approved by the Panel) and in the case of uncertificated holders by crediting their CREST accounts, will be made within 14 days of the receipt of such acceptances. Compulsory acquisition As described in the Offer Document, once Recipharm receives valid acceptances under the Offer in respect of, or otherwise acquires, 90 per cent. or more of Cobra Shares to which the Offer relates, and 90 per cent. or more of the voting rights attaching to Cobra's issued share capital, Recipharm intends to exercise its rights pursuant to Sections 974 to 991(inclusive) of the Companies Act 2006, to acquire compulsorily the remaining Cobra Shares for which it has not received valid acceptances of the Offer or otherwise acquired. Terms defined in the Offer Document have the same meaning in this announcement. Acorn Corporate Finance Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for Recipharm and no-one else in connection with the Offer and will not be responsible to anyone other than Recipharm for providing the protections afforded to clients of Acorn Corporate Finance Limited nor for providing advice in relation to the Offer, the content of this announcement, or any transaction, arrangement or matter referenced herein. Seymour Pierce Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for Cobra and no-one else in connection with the Offer and will not be responsible to anyone other than Cobra for providing the protections afforded to clients of Seymour Pierce Limited nor for providing advice in relation to the Offer, the content of this announcement, or any transaction, arrangement or matter referenced herein. Copies of the Offer Document, the Form of Acceptance and other documents on display for the purposes of the Offer are available for inspection during normal business hours on any business day at the offices of Cobbetts LLP, 70 Grays Inn Road, London, WC1X 8BT, throughout the period during which the Offer remains open for acceptance. This announcement is not intended to and does not constitute, or form any part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor shall there be any sale, issue or transfer of the securities referred to in this announcement in any jurisdiction in contravention of any applicable law. The Offer is made solely by means of the Offer Document and, in the case of certificated Cobra Shares, the Form of Acceptance accompanying the Offer Document. The Offer will not be made directly or indirectly in or into the United States, Canada, Australia, the Republic of South Africa or Japan. Accordingly, copies of this announcement are not being, and must not be, mailed or otherwise distributed or sent in or into or from the United States, Canada, Australia, the Republic of South Africa or Japan. The availability of the Offer to persons outside the United Kingdom may be affected by the laws of other jurisdictions. Such persons should inform themselves about and observe any applicable requirements of those jurisdictions. The Offer Document is available on Recipharm's website www.recipharm.com and on Cobra's website at www.cobrabio.com. and will continue to be made available on these websites free of charge whilst the Offer remains open for acceptance. Dealing Disclosure Requirements Under the provisions of Rule 8.3 of the City Code, if any person is, or becomes, "interested" (directly or indirectly) in 1 per cent. or more of any class of "relevant securities" of Cobra, all " dealings" in any "relevant securities" of Cobra (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3.30 pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the Offer becomes unconditional as to acceptances, lapses or is otherwise withdrawn or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of Cobra, they will be deemed to be a single person for the purpose of Rule 8.3. Under the provisions of Rule 8.1 of the City Code, all "dealings" in "relevant securities" of Cobra by Recipharm, must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction. A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed, and the number of such securities in issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk. "Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities. Terms in quotation marks are defined in the City Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a "dealing' under Rule 8, you should consult the Panel. Enquiries:
Danny Chapchal, Chairman Simon Saxby, Chief Executive Peter Coleman, CFO and Company Secretary
Carl-Johan Spak, Vice President
(Financial Adviser, Nominated Adviser and
Broker to Cobra)
Chris Howard
Christopher Wren
(Financial Adviser to Recipharm)
Harry Dutson
Tim Anderson The Directors of Cobra accept responsibility for the information contained in this announcement relating to Cobra, the Cobra Directors and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the Directors of Cobra (who have taken all reasonable care to ensure that such is the case) the information contained in this announcement for which they are responsible is in accordance with the facts and does not omit anything likely to impact the import of this announcement. The Directors of Recipharm accept responsibility for the information contained in this announcement other than relating to Cobra, the Cobra Directors and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the Directors of Recipharm (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement for which they are responsible is in accordance with the facts and does not omit anything likely to affect the import of such information. This information is provided by RNS The company news service from the London Stock Exchange END
OUPUBAVRRVAUAAR More |
||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| 11-11-09 |
BUY
Offer talks
|
|||
|
| ||||
|
| ||||
|
I'm assuming, maybe wrongly, that Sultan Scientific Limited, chaired by Sir John Banham, is involved in these talks. I note the recent investment agreement between Sultan and Cobra gave the former, "...the right to be provided with certain management information through its appointed board representative". I agree that even after this morning's substantial percentage increase, the share price could still have some way to go.
|
||||
| 11-11-09 | ||||
|
| ||||
|
| ||||
|
shown up 28% prior to going to market
|
||||
| 11-11-09 |
1
|
|||
|
| ||||
|
| ||||
|
IN DISCUSSIONS WHICH MAY OR MAY NOT LEAD TO AN OFFER BEING MADE FOR THE COMPANY.
|
||||
| 07-07-09 | ||||
|
| ||||
|
| ||||
|
spread very tight........... buy now!!!!!
|
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Discussion Board Terms & Conditions FSA Market Abuse Fact Sheet
More...